02.10.2017 • News

BASF Invests in China Amines Plant

(c) BASF
(c) BASF

BASF has announced plans to build a new specialty amines plant at its site in the Nanjing Chemical Industry Park in China. The facility will have a capacity of 21,000 t/y, mostly producing 1,2-propylenediamine (1,2-PDA), n-octylamine (n-OA) and polyetheramine (PEA), and will go on stream in 2019. Investment costs were not disclosed.

“This investment will help us to meet the increasing Asia-Pacific demand for specialty amines used as intermediates in a  diverse range of industries and applications, such as epoxy formulations, crop protection agents, spandex and  biocides for the coatings industry,”  said Narayan Krishnamohan, BASF’s senior vice president, Intermediates Asia-Pacific.

The German major, which claims to have the world’s most diverse portfolio of specialty amines, also produces 1,2-PDA and n-OA at Ludwigshafen, Germany, while PEA is made at Ludwigshafen, Gesimar in the US and Nanjing, China.

In March, BASF announced it would build a 42,000 t/y antioxidants plant in China. The new facility will be located at Caojing in Shanghai with production also scheduled to start in 2019.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read